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Summary
Poly (ADP-ribose) polymerase (PARP1) is a nuclear
protein that, when overactivated by oxidative stress-
induced DNA damage, ADP ribosylates target proteins
leading to dramatic cellular ATP depletion. We have
discovered a biologically active small-molecule inhib-
itor of PARP1. The discovered compound inhibited
PARP1 enzymatic activity in vitro and prevented ATP
loss and cell death in a surrogate model of oxidative
stress in vivo. We also investigated a new use for
PARP1 inhibitors in energy-deficient cells by using
Huntington’s disease as a model. Our results showed
that insult with the oxidant hydrogen peroxide de-
pleted cellular ATP inmutant cells below the threshold
of viability. The protective role of PARP1 inhibitors
against oxidative stress has been shown in this model
system.
Introduction
The products of oxidative stress, various oxidants, and
free radicals induce DNA strand breaks, triggering
PARP1 activation [1]. PARP1, one of the most abundant
proteins in the nucleus, can be activated up to 100-fold
by damaged DNA [2, 3]. This enzyme, which catalyzes
*Correspondence: akazantsev@partners.orgthe synthesis of poly ADP-ribose polymers on acceptor
proteins with NAD+ as substrate, is primarily responsible
for the catastrophic NAD+ and ATP loss observed under
conditions of high oxidative stress [4, 5]. In the absence
of functional PARP1, DNA base excision repair is de-
layed after exposure of cells to ionizing radiation or alky-
lating agents [6]. Over activated PARP1 may even cause
necrosis by depleting cellular energy sources beneath
the threshold of survival [7]. The use of bioenergetic mol-
ecules (NAD+) to build up biopolymers (poly-ADP-
ribose) in a highly processive manner for the purpose
of structural interference and signal transduction sug-
gests a unique role for PARP1 in cellular energy balance
and viability. A therapeutic approach, based on the
pharmacological inhibition of PARP1, was proposed for
a diverse and large group of human disorders. Here, we
report the discovery of a novel bioactive small-molecule
inhibitor of PARP1 and the therapeutic application of
PARP1 inhibitors for metabolically impaired cells.
Results and Discussion
Identification of a Novel PARP1 Inhibitor
We performed an in silico search of biologically active
scaffolds from our in-house compound library that
have been previously identified and examined in various
cell-based assays. Through this approach, we hoped to
limit our search to only those scaffolds that are known to
be active in a cell-based system, thus eliminating scaf-
folds that are toxic or not cell penetrable. In conducting
this search, we identified two candidate compounds,
CG1 and K245-14, with structural properties shared by
known PARP1 inhibitors (Figure 1A). Docking these
two compounds to the PARP1 active site with the ICM
program [8], we have obtained docking score values
lying in the same range as those of a selection of known
PARP1 inhibitors that we used as a reference (Figure 1H).
Moreover, the positions that the CG1 and K245-14 oc-
cupy in the binding pocket are highly similar to the posi-
tions of cocrystallized PARP1 ligands presented in PDB.
In particular, the amino group in these two molecules
makes hydrogen bonds to Ser-243 and Gly-202 (Fig-
ure 1I), which was suggested to be key for PARP-1 inhi-
bition [9], and aromatic rings are enclosed between
rings of Glu-179 and Tyr-235 (residue numbering form
PDB entry 1uk0 is used throughout this paper).
To determine if CG1 and K245-14 had PARP1 inhibi-
tory activity, we tested them in an in vitro PARP1 enzyme
assay, and they demonstrated inhibitory effects in a
dose-dependent manner (Figure 1B). CG1 and K245-14
yielded IC50 values of 2.5 mM and 2.0 mM, respectively
(Figures 1C and 1H).
We then attempted to find more potent PARP1 inhib-
itors, focusing ourselves on optimization of K245-14.
The 3D structure of K245-14 docked to the binding
pocket hinted to two directions of the lead optimization.
The first, more straightforward one is to modify aliphatic
side group of the molecule. It is this direction that we
pursued in the present study. From a database of avail-
able molecules, we selected seven analogs of K245-14
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hibitor Scaffolds
(A) Structures of known PARP1 inhibitors
used to screen in-house library and the two
novel structures found in the screen.
(B) In vitro PARP1 enzyme assay with two
novel structures and 3AB as a control.
(C) IC50 curve of K245-14.
(D) Analogs of K245-14 that showed PARP1
inhibition.
(E–G) IC50 curves of selected structures from
K245 series.
(H) Predicted versus measured values of
binding affinity for PARP-1 inhibitors. The
third and fourth columns are computed on
the basis of docking score values (second
column, see Experimental Procedures sec-
tion for details), and the fifth column con-
tains experimentally measured IC50 values.
(I) K245-14 docked to human PARP-1 active
site. The binding pocket is schematically
represented by its solvent accessible sur-
face. Dashed lines indicate hydrogen bonds.
Error bars represent the standard deviation
of the mean of three replicates.with variations in the desired group. Docking studies of
these molecules provided positions and docking score
values close to those of K245-14, indicating that the
molecules are likely to bind to PARP1. In enzyme-inhibi-
tion assays, all the molecules demonstrated PARP1 inhi-
bition, with the best inhibitor providing 10-fold increase
in potency over the original K245-14 compound (Figures
1E–1H).
Demonstration of Activity in Cultured Cells
Having demonstrated the in vitro inhibition of PARP1 by
CG1 and the K245 series, we sought to assess the bio-
logical activity of these new entities in a relevant cell-
based assay. The ability of PARP1 inhibitors to prevent
cellular ATP depletion under conditions of oxidative
stress is well documented [4, 10, 11]. In a surrogate
model of oxidative stress, cellular PARP1 is activated
in response to exposure of cells to hydrogen peroxide.
First, we validated the oxidative stress model of PARP1
activation with the known inhibitor 4-ANI. This highlypotent PARP1 inhibitor (IC50 = 180 nM) rescued oxidant-
dependent ATP loss in human (HeLa) and rat pheochro-
mocytoma (PC12) cell lines (Figures 2A and 2B). Next,
we assessed cell viability by measuring the activity of
mitochondrial dehydrogenases in a modified MTT assay
that utilizes the reagent WST-1. Mitochondrial dehydro-
genases are not regulated by the PARP1 pathway, thus
providing an objective cell viability read out independent
from PARP1 activation or inhibition. We demonstrated
hydrogen peroxide-dependent loss of cell viability in
both HeLa and PC12 cell lines and rescue of viability
loss with 4-ANI (Figures 2C and 2D). As anticipated,
we observed a good correlation between loss of ATP
and viability in both cell lines, with 4-ANI showing effi-
cacy in both ATP and WST-1 assays in HeLa and in
PC12 cells.
After establishing the cellular oxidative stress model,
we tested CG-1 and the K245 series of active inhibitors.
Surprisingly, only compound K245-14 demonstrated
consistent and notable rescue in both assays (Figures
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analog of K245-14, showed slight rescue only under
conditions of severe oxidation (data not shown). We ex-
tended our tests to two known highly potent in vitro
PARP1 inhibitors EB47 (IC50 = 45 nM) and PJ34 (IC50 =
20 nM). While EB47 failed to block ATP depletion and
rescue viability loss, PJ34 was highly effective in both
Figure 2. Novel PARP1 Inhibitor Rescues Peroxide-Induced Loss
of ATP and Cell Viability
(A) HeLa cells treated with various concentrations of H2O2 for 2 hr
(6) pretreatment for 1 hr with 4-ANI after which cells were assayed
for total ATP levels.
(B) Same as in (A) except with PC12 cells.
(C) HeLa cells were treated with various concentrations of H2O2 for
2 hr (6) pretreatment for 1 hr with 4-ANI after which 1/10 cell culture
volume of WST1 reagent was added. Cells were incubated for 1 hr
after which Abs450 was measured.
(D) Same as in (C) except with PC12 cells.
(E) ATP assay on PC12 cells pretreated for 1 hr with the indicated
compounds, followed by exposure to 400 mM H2O2 for 2 hr.
(F) WST1 assay on PC12 cells pretreated for 1 hr with the indicated
compounds, followed by exposure to 400 mM H2O2 for 2 hr.
(G) ATP assay on PC12 cells with potent in vitro PARP1 inhibitors.
(H) WST1 assay on PC12 cells treated with the same inhibitors.
Asterisk, p < 0.05; double asterisk, p < 0.01; triple asterisk, p <
0.001 versus peroxide only treatment.
Error bars represent the standard deviation of the mean of three
replicates.assays (Figures 2G–2H). The effects of K245-14 and
PJ34 were similar in magnitude, with both compounds
rescuing 50% of ATP depletion and 25% of viability
loss. Viability tests on K245-14 from 0.01–25 mM did
not reveal any apparent loss of viability. We have ad-
vanced K245-14 as a lead compound for further potency
and ADMET optimization. Our results suggest, however,
that high potency of PARP1 inhibition in vitro does not
necessarily lead to a robust biological response. Using
the tools of computational chemistry, we envision the ra-
tional optimization of lead compound K245-14, followed
by empirical testing in in vitro and cell-based assays.
Our data provide the basis for development of a
screening platform to search for bioactive small-mole-
cule PARP1 inhibitors, utilizing the oxidant treatment of
cells combined with ATP rescue or cell viability read-
outs. This approach has been validated in a pilot screen
of 2000 compounds to demonstrate the feasibility of a
cell-based screen for PARP1 inhibitors (data not shown).
Application of PARP1 Inhibitors
for Energy-Deficient Cells
Next, we set out to explore new therapeutic applications
for PARP1 inhibitors. We reasoned that metabolically
impaired and energy-deficient cells will be more vulner-
able to robust ATP depletion, mediated by activated
PARP1, than normal counterparts. In cells where ATP
levels are already lower than normal due to, for example,
mitochondrial impairment, activation of PARP1 may se-
riously compromise cellular functions and viability [12].
In Huntington’s disease (HD), an autosomal dominant
disorder, mitochondrial dysfunction and ATP deficiency
have been implicated in disease pathology; however,
the precise mechanism(s) of neurodegeneration re-
mains elusive [13]. Huntington’s disease is character-
ized by progressive neuronal cell loss in the striatum
and the cortex. Energy deficits likely compound the
influence of molecular and environmental stresses and
increase the vulnerability of neurons in HD [14]. PARP1
activation, in response to DNA damage caused by oxi-
dative stress or by intracellular oxidation, may lead to
further decrease of ATP levels below the threshold of
normal cell function and viability in energy-deficient
mutant HD cells [15, 16, 17]. Appropriate PARP1 activa-
tion as a component of cellular defense mechanisms in
wild-type cells makes energy-deficient HD cells vulnera-
ble due to unsustainable loss of ATP. Hence, we pro-
pose that prevention of ATP loss in energy-deficient mu-
tant HD cells with small-molecule inhibitors of PARP1
may provide therapeutic benefits and should be tested.
To this end, we have assessed the ability of 4-ANI and
K245-14 to prevent ATP loss in human Huntington’s dis-
ease and normal lymphoblastoid cells, as well as in mu-
tant and wild-type mouse striatal cells (Figures 3A–3D).
We also observed the previously reported reduced
ATP levels in all mutant cell lines relative to normal con-
trols [18]. Treatment of cells with the oxidant H2O2
caused ATP loss in both wild-type and mutant cells.
While the small-molecule inhibitors 4-ANI and K245-14
prevented the loss of ATP in both mutant and normal
murine and human cells, the benefits of PARP1 inhibi-
tion for severely energy-depleted HD cells were readily
apparent (Figures 3A, 3B, and 3D). Absolute rescued
residual ATP levels in treated cells were dependent on
Chemistry & Biology
768Figure 3. Use of HD as a Model for Potentially Novel Application for
PARP1 Inhibitors
(A) Effect of 10 mM 4-ANI preincubated for 1 hr on ATP levels in
wild-type (white bars) and two mutant HD (black bars) lymphoblas-
toid cell lines with (+) or without (2) 200 mM H2O2 for 2 hr. Triple as-
terisk, p < 0.001 versus H2O2 alone treated cells.
(B) Wild-type (white bars) and mutant (black bars) lymphoblastoid
cells preincubated with K245-14 for 1 hr, followed by treatment
with (+) or without (2) 200 mM H2O2 for 2 hr. Asterisk, p < 0.05; dou-
ble asterisk, p < 0.01; triple asterisk, p < 0.001 versus H2O2 alone
treated cells.
(C) Basal ATP levels in wild-type STHdhQ7/Q7 and mutant
STHdhQ111/Q111 striatal cells.
(D) Wild-type (white bars) and mutant (black bars) striatal cells pre-
incubated with indicated compounds for 1 hr followed by treatment
with 400 mM H2O2 for 2 hr. Asterisk, p < 0.05; double asterisk, p <
0.01; triple asterisk, p < 0.001 versus H2O2 alone treated cells.
(E) PARP1 protein levels in untreated wild-type STHdhQ7/Q7 and
mutant STHdhQ111/Q111 striatal cells, and in wild-type (30/24
CAG), and mutant HD (63/24 CAG) lymphoblastoid cells.
(F) Western blot of PARP1 expression in wild-type and R6/2 trans-
genic mouse cortexes alongside recombinant PARP1 (lane 1).
(G) PARP1 enzyme activity levels for wild-type and transgenic
mouse cortexes. For this assay, mouse cortex extracts were used
in place of recombinant PARP1 in the standard enzyme assay.
Asterisk, p < 0.05; double asterisk, p < 0.01 versus no DNA
activation.
Error bars represent the standard deviation of the mean of three
replicates.the basal ATP levels in unstressed mutant and wild-type
cells, compound potencies of PARP1 inhibitors (Figures
3A–3D), and the severity of the stress as defined by H2O2
concentrations (not shown). Similar results were
achieved in cells treated with the DNA-damaging agent
methyl nitrosourea (MNU), although ATP loss in HD
and wild-type cells was not robust and significant only
at high concentration (5 mM) of MNU. Notably, the inhib-
itors were ineffective in preventing ATP loss mediated
by the mitochondrial toxin, 3-nitropropionic acid
(3-NP) when using STHdhQ7/Q7 and STHdhQ111/Q111
striatal cells [19], demonstrating specificity for PARP1
inducing agents (not shown). Since the basis for the
mitochondrial defect in Huntington’s disease is un-
known, we limited our experiments to measurement
of PARP1-dependent ATP levels and did not include
the mitochondrial dehydrogenase-dependent WST-1
assay. We have measured and detected no effect of
PARP1 inhibitors on basal ATP levels in normal and
HD lymphoblastoid cells or in wild-type and mutant
striatal cells in the absence of induced PARP1 activa-
tion. This suggests that PARP1 activity is not responsi-
ble for mitochondrial defects and the reduction of basal
ATP levels. Furthermore, we have not discovered differ-
ences in PARP1 protein levels (Figure 3E), in PARP1
basal activities, and in rate of PARP1 activation in
mutant HD and normal cells (not shown). However, in
both striatal cell lines PARP1 expression levels were
quite low, which might explain their resistance to high
concentrations of H2O2 (data not shown). Further, we
have tested PARP1 levels in mouse cortexes, the brain
area affected in Huntington’s disease. Extracts were
prepared from cortexes of wild-type and HD transgenic
R6/2 mice, sacrificed at 80 days, when the process of
neurodegeneration has started. We did not observe
any difference in the level of PARP1 expression between
wild-type and HD samples (Figure 3F). The observed
doublet at 116 kDa may be attributable to posttransla-
tional modification. A faint band was observed at
85 kDa (not shown), indicative of PARP1 cleavage, al-
though this band was equally present in both wild-type
and transgenic samples. Finally, we tested and ob-
served the same magnitude of PARP1 activation in
wild-type and HD cortex extracts, supplemented with
damaged DNA (Figure 3G). These data suggest that
HD cells have normal functional PARP1, which upon ac-
tivation can deplete ATP levels of mutant cells further
below the threshold of viability.
Small-molecule inhibitors effectively protect HD cells
from PARP1-dependent energy depletion, triggered by
stimuli such as oxidative stress. Our results suggest
that PARP1 activation could be a significant contributing
factor to the pathological reduction of energy resources
that occurs in HD. To assess the therapeutic potential of
PARP1 pharmacological inhibition, we propose optimiz-
ing lead compound K245-14 for potency and ADMET,
conduct pharmacology studies, and advance selected
analogs to efficacy trials in HD mouse models.
Significance
PARP1 was proposed as a useful drug target for a
broad and diverse group of human disorders. To iden-
tify bioactive small-molecule inhibitors of PARP1, we
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scaffolds that we have previously identified and exam-
ined in various cell-based assays. By conducting a
search, we identified candidate compounds belonging
to two novel scaffolds that demonstrated PARP1 inhi-
bition activity in vitro. To demonstrate the biological
activity of our novel inhibitors, we developed two
PARP1-dependentcell-basedassays.Theexperiments
yielded a lead compound, performing in live cells con-
sistently and selectively with respect to inhibition of
PARP1 target. Notably, not all highly potent in vitro
known PARP1 inhibitors also tested were biological
active. Furthermore, magnitudes of biological effects
were the same for known and novel PARP1 inhibitors,
suggesting that biological activities in vivo depend
on other important properties of small molecules and
are not limited to high potency of inhibition in vitro.
Based on our results, we proposed to identify novel
bioactive small molecules by using a cell-based
screening platform, which utilizes oxidant treatment
of cells combined with ATP rescue or cell viability
read outs. Further, we explored a new therapeutic
application for PARP1 inhibitors in metabolically im-
paired and energy-deficient cells. Huntington’s dis-
ease cells from patients and transgenic mice showed
energy deficiency due to mitochondrial impairment.
Low basal ATP levels in mutant cells made them
more sensitive than normal counterparts to robust en-
ergy depletion, mediated by PARP1. We demonstrated
significant reduction of ATP levels in mutant cells in
response to oxidant treatment and rescue of energy
depletion with PARP1 inhibitors. Novel and known in-
hibitors selectively protected cells against acute oxi-
dative stress. Lastly, we have shown that PARP1 was
functional in brain extracts from transgenic HD, and
therefore, pharmacological inhibition of PARP1 acti-
vation could be neuroprotective.
Experimental Procedures
Compounds
Chemical entities CG1 (MW 184, H_acceptors 1, H_donors 3, logP
0.94, logD 1.34, logSw 21.74) and K245-14 (MW 352, H_acceptor
3, H_donors 3, logP2.37, logD 1.05, logSw 20.083) for study were
synthesized at and obtained from Chemical Diversity (San Diego).
PARP1 inhibitors 3-AB and 4-ANI were purchased from Trevigen
and Calbiochem respectively.
Cell Culture
HeLa cells were cultured in DMEM with 10% FBS. Human lympho-
blast cells derived from HD patients carrying either one mutant
and one wild-type HD allele (69/17 CAG and 63/24 CAG) or two
wild-type alleles (20/18 CAG and 30/24 CAG) were cultured in
RPMI 1640 with 10% FBS, 2 mM L-glutamine, and 100 mg/ml penicil-
lin/streptomycin. STHdhQ7/Q7 and STHdhQ111/Q111 striatal cells, ex-
pressing endogenous mutant huntingtin with 111-glutamines or
endogenous wild-type huntingtin with 7-glutamines, respectively,
have been described elsewhere [20]. Previously reported PC12 cells
with an integrated HD103Q-EGFP construct, expressing the first 17
N terminus amino acids of huntingtin with 103 glutamines, tagged
with EGFP, were cultured in DMEM containing 10% horse serum,
5% FBS, 2 mM L-glutamine, 200 mg/ml G418, and 100 mg/ml zeocin.
Lymphoblast and PC12 cultures were kept at 37C and 5% CO2 in
a humidified chamber.
High-Throughput Screening
High-throughput screen was carried out with a 1860 compound
library from Timtec consisting of naturally derived products. Com-pounds were dispensed into assay plates with an EP3 liquid handler
(PerkinElmer), and plates were read on a Wallac Victor2V plate
reader (PerkinElmer).
ATP Assay
For determinations of ATP levels in PC12, lymphoblastoid, and stria-
tal cells, cells were plated to 50% confluency in 96-well plates
and allowed to attach, after which cells were treated with various
concentrations of either hydrogen peroxide (H2O2) diluted in PBS,
3-nitropropionic acid (3-NP) dissolved in PBS/0.2N NaOH to
200 mM to keep the pH neutral, or methyl nitrosourea (MNU) dis-
solved in PBS to 100 mM. ATP measurements were performed
with cells treated with hydrogen peroxide for 2 hr, with 3-NP for 2,
24, 48, and 72 hr, and with MNU for 1, 2, and 6 hr. Lymphoblastoid
cells were plated in 24-well plates and incubated with the stress in-
ducing agents for 2 hr. Cells were pelleted prior to lysis. After incu-
bation with stress inducing reagents, the cells were lysed in RIPA
buffer, and total protein quantified with the BCA protein assay kit
(Pierce). Triplicate aliquots of normalized extract were mixed with
equal volumes of ATPlite reagent, and luminescence measured in
a Victor2V plate reader.
The CellTiter GLO Luminescent cell viability kit (Promega) was
used for the determination of ATP levels in the NP3-treated striatal
cells. 20,000 cells/well were plated in a black opaque-walled
96-well plate (Packard Bioscience) and incubated overnight. The
cells were then treated with different concentrations of K245-14
and 4-ANI, in presence or absence of 1 mM 3-NP for 48 hr, adjusting
the concentration of mock (DMSO) to 0.1% for all the treatments.
Following the incubation, cell lysis was induced by adding Cell-
Titer-GLO reagent to each well and mixing on a shaker for 2 min. An
ATP standard curve was prepared in the same plate. The plate was
dark adapted for 10 min to stabilize the luminescence signal, which
was then recorded with a microplate luminometer (MicroLumat Plus
LB 96V, Berthold Technologies) with a 30 s recording time.
PARP Assay
PARP assays were carried out with the Universal Colorimetric PARP
activity assay kit (Trevigen) according to the manufacturer’s instruc-
tions. To measure the basal PARP1 activities in the enzymatic assay,
the cell extracts were not supplemented with exogenous damaged
DNA.
Western Blot Analysis
To determine cellular levels of PARP protein, cells were lysed for
30 min on ice in PARP buffer containing 0.3 M NaCl, 1 mM PMSF,
and a protease inhibitor cocktail. Lysates were then centrifuged
for 10 min at 10,000 3 g, and the resulting supernatant quantified
by BCA. Twenty-five milligrams of protein was loaded and separated
on a 10% polyacrylamide gel. Samples were transferred to a PVDF
membrane, blocked in 5% nonfat milk in PBST, and probed with
an anti PARP MAb (C2-10, Trevigen) at 1:2000. Blots were washed
with PBST and probed with an HRP-conjugated anti-mouse second-
ary antibody and visualized by using ECL.
Molecular Modeling
In the Protein Data Bank (PDB), there are three X-ray structures of
human PARP1 having resolution 3A˚ (PDB codes: 1UK0, 1UK1, and
1WOK) and seven X-ray structures of nonhuman PARP1 from which
the structure 1A26 representing chicken PARP1 has the best resolu-
tion of 2.25A˚. To take favor of both structure identity and higher res-
olution, in this study, we used both human (1UK0) and chicken
(1A26) 3D structures for molecular docking. For the molecular mod-
eling calculations, we used ICM program (reference is given above).
The binding site was identified with ICM binding pocket location
algorithm. In the 1A26 structure, the only side chain in the binding
site that differs from that of human PARP1 is GLN-673. We mutated
it numerically to glutamic acid to mimic human PARP1. For both 3D
structures, we minimized side chained with ICM biased probability
Monte Carlo method [21] and then minimized the entire structures
with ICM local minimization in the presence of native ligand con-
tained in 1UK0. We performed docking of the studied molecules to
both of the structures. The docking score values obtained with the
two structures are very close to each other with linear correlation co-
efficient R2 = 0.96. In this paper, we present only docking score
Chemistry & Biology
770values obtained with 1UK0 structure. To determine a characteristic
scale of docking score for PARP1 inhibitors, we docked ten known
inhibitors to the PARP1 binding site (structures not presented).
These reference inhibitors exhibited score values in the range from
35 to 100 ICM score units. We used the obtained score values to
calibrate ICM docking score to the experimental binding energy
values by linear transformation E = A S + B, where S is ICM score
and A and B are constants determined by least squares fit of
the score values to binding energies. We used the following approx-
imate relation between binding energy and binding affinity: E =
Log10(Kd/1 Mol)3 1.4 kcal/Mol, binding affinity being given by disso-
ciation constant Kd.
Statistics
Experiments were repeated two to three times, and a representative
example is shown. Significance values between samples were ob-
tained by the Student’s t test with p values < 0.05 (marked with an
asterisk) considered significant (double asterisk, p < 0.01; triple as-
terisk, p < 0.001); for all p values, n = 3. Values are represented as the
mean 6 SD.
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